Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 85

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 85
---
) requirements were met with respect to the fiscal year ended December 31, 2024, except as follows: one Form 4 for Frank Stokes covering one transaction was filed late on August 13, 2024 as the result of an administrative error.

#### 80Castle Biosciences 2025 Proxy Statement
| Equity Compensation Plan 
 Information              |

The following table provides certain information with respect to all of the Company’s equity compensation plans in effect as of December 31, 2024:

| Plan category                                                 |     | Number of securities to be issued upon exercise of outstanding options, warrants and rights 
 (a)(2)                                                                                      |           |     | Weighted-average exercise price of outstanding options, warrants and rights 
 (b)(3)                                                                      |       |     |           |     |    |     | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
 (c)                                                                                                                                         |
|:--------------------------------------------------------------|:----|:--------------------------------------------------------------------------------------------|----------:|:----|:----------------------------------------------------------------------------|------:|:----|----------:|:----|---:|:----|:--------------------------------------------------------------------------------------------------------------------------------------------|
| Equity compensation plans approved by security holders(1)     |     |                                                                                             | 5,962,980 |     | $                                                                           | 36.23 |     | 1,838,654 |     | -4 |     |                                                                                                                                             |
| Equity compensation plans not approved by security holders(5) |     |                                                                                             |   500,034 |     |                                                                             |     — |     |   191,156 |     |    |     |                                                                                                                                             |
| Total                                                         |     |                                                                                             | 6,463,014 |     | $                                                                           | 36.23 |     | 2,029,810 |     |    |     |                                                                                                                                             |

(1) Consists of the 2008 Plan, the 2018 Plan, the 2019 Plan and the Castle Biosciences, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”). Additional information on these equity plans is set forth in Note 15 to our consolidated financial statements appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

(2) Consists of outstanding options to purchase 161,160 shares of common stock under the 2008 Plan, outstanding options to purchase 270,026 shares of common stock under the